DHCPL

Communicating safety information to patients and healthcare professionals is a public health responsibility, and is essential in promoting the safe and rational use of medicines, and preventing harm from adverse reactions.

This webpage serves to provide the public and healthcare professionals with easy access to important drug safety information, as approved by SAHPRA. Safety alerts provide important information and recommendations about therapeutic products; however, it does not necessarily imply that a product is considered unsafe.

Abic Vincristine 1 mg/ml; 2 mg/2 ml

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Abitrexate 2,5 mg; 5 g/50 ml; 50 mg/2 ml; 500 mg/20 ml; 1000 mg/10 ml

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Bupyra XL 150/300

Toggle Expand/Collapse

This relates to the risk of Brugada syndrome associated with the use of bupropion-containing medicines.

View PDF

Carbosin 150 mg/15 ml; 450 mg/45 ml; 600 mg/60 ml

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Fluoroquinolone antibiotics: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones.

View PDF

Dasatinib Teva 20/50/70/100

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Docetaxel Teva 20 mg; 80 mg

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Doxorubicin-Sol PCH 10 mg/50 mg

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Eposin 100 mg/5 ml

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Fluracedyl 250/500/1000/5000

Toggle Expand/Collapse

Fluoropyrimidine containing medicines and related substances: increased drug exposure and toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.

View PDF

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Increased risk of subclinical acute interstitial nephritis associated with the use of proton pump inhibitors (PPIs) leading to acute kidney injury and/or chronic renal failure.

View PDF

Nurika 25/50/75/150; Pregabalin Ivax 25/50/75/150

Toggle Expand/Collapse

This relates to the risk of serious breathing difficulty associated with the use of gabapentinoids (gabapentin and pregabalin).

View PDF

Oxaliplatin PCH 50 mg/10 ml; 100 mg/20 ml

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

PCH-Paclitaxel 30 mg; 100 mg; 300 mg

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Teva Carbilevo 25/100; 25/250

Toggle Expand/Collapse

Dopaminergic medicines used in the treatment of Parkinson’s Disease: risk of dopamine dysregulation syndrome (DDS).

View PDF

Teva Fludarabine 50 mg/2ml

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF

Vinblastine Teva 10

Toggle Expand/Collapse

Recommended calculation of contraception duration after completion of therapy to minimise the risk of genotoxic anticancer-mediated reproductive adverse events.

View PDF